Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $47.00

Stoke Therapeutics (NASDAQ:STOK – Free Report) had its price objective hoisted by HC Wainwright from $35.00 to $47.00 in a research report report published on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock. STOK has been the topic of a number of other research reports. Needham & Company LLC reaffirmed a […]

Leave a Reply

Your email address will not be published.

Previous post First-time homeownership slips further out of reach without family assistance
Next post Athersys (NASDAQ:ATHX) Now Covered by StockNews.com